AR088875A1 - Forma de dosis farmaceutica oral a prueba de manipulacion - Google Patents
Forma de dosis farmaceutica oral a prueba de manipulacionInfo
- Publication number
- AR088875A1 AR088875A1 ARP120104298A ARP120104298A AR088875A1 AR 088875 A1 AR088875 A1 AR 088875A1 AR P120104298 A ARP120104298 A AR P120104298A AR P120104298 A ARP120104298 A AR P120104298A AR 088875 A1 AR088875 A1 AR 088875A1
- Authority
- AR
- Argentina
- Prior art keywords
- proof
- handling
- oral pharmaceutical
- dose form
- pharmaceutical dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Addiction (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una forma de dosis farmacéutica para la administración oral que tiene una resistencia a la ruptura de por lo menos 300 N y que comprende (i) un ingrediente farmacológicamente activo; (ii) un antagonista opioide y/o un agente repelente; (iii) un óxido de polialquileno que tiene un peso molecular promedio de por lo menos 200,000 g/moles; y (a) comprende (iv) un polímero aniónico; y/o (b) tiene una estabilidad de almacenamiento a 40ºC de por lo menos 3 meses.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11009129 | 2011-11-17 | ||
EP12001295 | 2012-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR088875A1 true AR088875A1 (es) | 2014-07-16 |
Family
ID=47191746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120104298A AR088875A1 (es) | 2011-11-17 | 2012-11-15 | Forma de dosis farmaceutica oral a prueba de manipulacion |
Country Status (17)
Country | Link |
---|---|
US (1) | US20130129826A1 (es) |
EP (1) | EP2780000B1 (es) |
JP (1) | JP6085307B2 (es) |
KR (1) | KR20140096062A (es) |
CN (1) | CN104066426A (es) |
AR (1) | AR088875A1 (es) |
AU (1) | AU2012338872B2 (es) |
BR (1) | BR112014011504A2 (es) |
CA (1) | CA2855718A1 (es) |
CL (1) | CL2014000904A1 (es) |
CO (1) | CO7210299A2 (es) |
EA (1) | EA201400590A1 (es) |
HK (1) | HK1200742A1 (es) |
IL (1) | IL232054A0 (es) |
MX (1) | MX349725B (es) |
PE (1) | PE20141671A1 (es) |
WO (1) | WO2013072395A1 (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
EP1610767B1 (en) | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
BRPI0906467C1 (pt) | 2008-01-25 | 2021-05-25 | Gruenenthal Gmbh | forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada |
KR101690094B1 (ko) | 2008-05-09 | 2016-12-27 | 그뤼넨탈 게엠베하 | 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법 |
WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
WO2011009604A1 (en) * | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
PE20121067A1 (es) | 2009-07-22 | 2012-09-05 | Gruenenthal Chemie | Forma de dosificacion de liberacion controlada extruida por fusion en caliente |
WO2012028319A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
CA2808541C (en) | 2010-09-02 | 2019-01-08 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
AR087360A1 (es) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
KR20140053158A (ko) | 2011-07-29 | 2014-05-07 | 그뤼넨탈 게엠베하 | 즉시 약물 방출을 제공하는 탬퍼-저항성 정제 |
CA2864949A1 (en) | 2012-02-28 | 2013-09-06 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
JP6282261B2 (ja) | 2012-04-18 | 2018-02-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 不正使用防止および過量放出防止医薬剤形 |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
JP2015521988A (ja) | 2012-07-06 | 2015-08-03 | イガレット・リミテッド | 制御放出用乱用防止性医薬組成物 |
MX362838B (es) * | 2012-07-12 | 2019-02-19 | SpecGx LLC | Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente. |
CA2913209A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper resistant dosage form with bimodal release profile |
EP3003279A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
CN103304570A (zh) * | 2013-07-12 | 2013-09-18 | 四川省惠达药业有限公司 | 一种盐酸纳洛酮化合物、其制备方法及其药物组合物 |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
MX371372B (es) | 2013-11-26 | 2020-01-28 | Gruenenthal Gmbh | Preparacion de una composicion farmaceutica en polvo por medio de criomolienda. |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
CA2929866A1 (en) * | 2013-12-23 | 2015-07-02 | Purdue Pharma L.P. | Opioid antagonist formulations |
CA2947786A1 (en) | 2014-05-12 | 2015-11-19 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
JP6371463B2 (ja) | 2014-07-17 | 2018-08-08 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 即時放出性乱用抑止性液体充填剤形 |
EP3174534A1 (en) * | 2014-08-01 | 2017-06-07 | KRKA, d.d., Novo mesto | Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters |
EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
CN107205943A (zh) * | 2014-12-08 | 2017-09-26 | 德威洛克制药有限公司 | 纳洛酮单剂和多层片剂 |
JP2018517676A (ja) | 2015-04-24 | 2018-07-05 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 即時放出および溶媒抽出に対する耐性を有する改変防止製剤 |
CA2983634A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from particles |
WO2016170093A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix |
JP2018513872A (ja) | 2015-04-24 | 2018-05-31 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 異なる粒子から2種の薬物の急速放出をもたらすタンパレジスタントな固定用量組合せ |
JP2018520165A (ja) * | 2015-07-10 | 2018-07-26 | サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドSun Pharma Advanced Research Company Limited | ヒドロコドンの多数錠剤乱用抵抗性即時放出型固体投薬形態物 |
DE202016005375U1 (de) * | 2015-09-03 | 2016-09-30 | Acino Pharma Ag | Verminderung der Deallylierung von Naloxon während der Lagerung einer naloxonhaltigen Retardformulierung |
WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
ES2967689T3 (es) | 2018-04-06 | 2024-05-03 | Capsugel Belgium Nv | Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)] |
CN115337440B (zh) * | 2022-08-22 | 2024-03-29 | 南通大学 | 一种促进伤口复原的纳米敷料及其制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69709646T2 (de) | 1996-03-12 | 2002-08-14 | Alza Corp., Palo Alto | Zusammensetzung und dosisform mit einem opioid-antagonisten |
CN1525851A (zh) * | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | 抗滥用阿片样物质控释剂型 |
AU2002321879A1 (en) | 2001-08-06 | 2003-03-03 | Thomas Gruber | Pharmaceutical formulation containing dye |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
DK2425824T5 (en) | 2002-04-05 | 2018-02-12 | Mundipharma As | Pharmaceutical preparation containing oxycodone and naloxone |
US20070048228A1 (en) * | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
PL1842533T3 (pl) * | 2003-08-06 | 2013-08-30 | Gruenenthal Gmbh | Postać aplikacyjna zabezpieczona przed nadużyciem |
DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
PL1740156T3 (pl) | 2004-04-22 | 2011-12-30 | Gruenenthal Gmbh | Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej |
PL1765303T5 (pl) | 2004-07-01 | 2023-05-22 | Grünenthal GmbH | Tabletka doustna zabezpieczona przed nadużywaniem |
WO2006002886A1 (de) | 2004-07-01 | 2006-01-12 | Grünenthal GmbH | Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
AR049839A1 (es) | 2004-07-01 | 2006-09-06 | Gruenenthal Gmbh | Procedimiento para la produccion deuna forma farmaceutica solida, protegida frente al abuso |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US10960077B2 (en) * | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
EP2367541B1 (en) * | 2008-12-16 | 2014-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
GB0909680D0 (en) | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
CA2808541C (en) * | 2010-09-02 | 2019-01-08 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
CN103476401A (zh) * | 2011-02-17 | 2013-12-25 | Qrx制药有限公司 | 用于预防固体剂型滥用的技术 |
CN103998025A (zh) * | 2011-10-06 | 2014-08-20 | 格吕伦塔尔有限公司 | 包含阿片样物质激动剂和阿片样物质拮抗剂的防篡改口服药物剂型 |
-
2012
- 2012-11-15 US US13/677,446 patent/US20130129826A1/en not_active Abandoned
- 2012-11-15 EP EP12787711.6A patent/EP2780000B1/en not_active Not-in-force
- 2012-11-15 AU AU2012338872A patent/AU2012338872B2/en not_active Ceased
- 2012-11-15 MX MX2014005820A patent/MX349725B/es active IP Right Grant
- 2012-11-15 WO PCT/EP2012/072678 patent/WO2013072395A1/en active Application Filing
- 2012-11-15 PE PE2014000627A patent/PE20141671A1/es not_active Application Discontinuation
- 2012-11-15 KR KR1020147013076A patent/KR20140096062A/ko not_active Application Discontinuation
- 2012-11-15 CN CN201280056414.5A patent/CN104066426A/zh active Pending
- 2012-11-15 JP JP2014541653A patent/JP6085307B2/ja not_active Expired - Fee Related
- 2012-11-15 CA CA2855718A patent/CA2855718A1/en not_active Abandoned
- 2012-11-15 AR ARP120104298A patent/AR088875A1/es unknown
- 2012-11-15 EA EA201400590A patent/EA201400590A1/ru unknown
- 2012-11-15 BR BR112014011504A patent/BR112014011504A2/pt not_active IP Right Cessation
-
2014
- 2014-04-09 CO CO14077088A patent/CO7210299A2/es unknown
- 2014-04-10 CL CL2014000904A patent/CL2014000904A1/es unknown
- 2014-04-10 IL IL232054A patent/IL232054A0/en unknown
-
2015
- 2015-02-11 HK HK15101505.9A patent/HK1200742A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20140096062A (ko) | 2014-08-04 |
CN104066426A (zh) | 2014-09-24 |
BR112014011504A2 (pt) | 2017-05-09 |
CA2855718A1 (en) | 2013-05-23 |
AU2012338872B2 (en) | 2017-06-22 |
JP6085307B2 (ja) | 2017-02-22 |
CL2014000904A1 (es) | 2014-08-18 |
EP2780000A1 (en) | 2014-09-24 |
MX349725B (es) | 2017-08-10 |
EP2780000B1 (en) | 2019-04-03 |
US20130129826A1 (en) | 2013-05-23 |
AU2012338872A1 (en) | 2014-04-17 |
HK1200742A1 (en) | 2015-08-14 |
IL232054A0 (en) | 2014-05-28 |
WO2013072395A1 (en) | 2013-05-23 |
JP2014533668A (ja) | 2014-12-15 |
EA201400590A1 (ru) | 2014-11-28 |
PE20141671A1 (es) | 2014-11-22 |
MX2014005820A (es) | 2014-06-04 |
CO7210299A2 (es) | 2015-03-09 |
NZ623291A (en) | 2016-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR088875A1 (es) | Forma de dosis farmaceutica oral a prueba de manipulacion | |
AR096439A1 (es) | Forma de dosificación resistente al uso indebido que contiene una o más partículas | |
ECSP14013269A (es) | Forma de dosificación resistente a la alteración comprendiendo agonista opioide y antagonista opioide | |
ES2487244T3 (es) | Forma de dosificación resistente a la manipulación que comprende un polímero aniónico | |
CY1120783T1 (el) | Ανθεκτικη εναντι παραβιασης και ανθεκτικη εναντι μεταποθηκευσης δοσης φαρμακευτικη μορφη δοσολογιας | |
CY1119829T1 (el) | Βιοαποικοδομησιμες συνθεσεις απελευθερωσης φαρμακου | |
ECSP12011590A (es) | Forma de dosificación de oxidación estabilizada resistente a la manipulación | |
ECSP13012474A (es) | Forma de dosificación resistente a manipulación que comprende una sal inorgánica | |
ECSP13012473A (es) | Forma de dosificación resistente a alteración que comprende un polímero aniónico | |
MX2014013095A (es) | Forma de dosificacion farmaceutica termoconformada, resistente al uso indebido, que contiene zinc. | |
EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
EA201690679A1 (ru) | Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан | |
EA201291104A1 (ru) | Пероральные лекарственные формы бендамустина | |
ECSP14000928A (es) | Forma de dósis farmacéutica oral a prueba de manipulación que comprende un agente antagonista y/o repelente opioide, óxido de polialquileno y un polímero aniónico | |
CL2012001641A1 (es) | Compuestos derivados de piperazina; composición farmacéutica; que comprende a uno de los compuestos y uso de los compuestos en la preparación de medicamentos para el tratamiento y/o prevención de infecciones por protozoos, en forma particular para el tratamiento y/o prevención de la malaria. | |
AR080541A1 (es) | Tratamiento para la endometriosis | |
CY1119701T1 (el) | Σταθερη φαρμακευτικη συνθεση που περιεχει υδροχλωρικη βαρδεναφιλη | |
CL2012000499A1 (es) | Forma de dosificación farmacéutica sólida oral de liberación extendida que comprende una formulación matricial de liberación extendida que comprende 5 a 500 mg de clorhidrato de oxicodona y al menos 80 % (p/p) de oxido de polietileno (pm 1.000.000); y su uso para tratar el dolor (div. sol. n° 200702485). | |
UA110792C2 (uk) | Лікарська форма бендамустину для перорального застосування | |
CL2012003685A1 (es) | Kit farmaceutico que comprende una o mas unidades de envasado que comprenden 21 a 28 unidades de dosificacion activas diarias en que cada una comprende por lo menos 2 mg de drosperidona, sin estrogernos; uso del kit y de una composicion farmaceutica que comprende drosperidona para preparar un medicamento util como anticonceptivo. | |
IN2013MU03567A (es) | ||
UA105513C2 (uk) | Лікарська форма уповільненого вивільнення глюкозаміну | |
TH127248B (th) | ปริมาณขนาดยาที่ให้ทางปากของเบนดามัสทีน (oral dosage forms of bendamustine) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |